Finance

Lists
Q3 2026 earnings • released • EPS miss -15.23%
See results
ERAS:NASDAQ
Erasca Inc
$15.78
-6.07%
(-1.02) 1D
$15.71
-0.44% (-0.070)
Pre-market
Closed: Nov 12, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ERAS...
Open
$16.22
High
$16.27
Low
$15.16
Mkt. cap
5.52B
Avg. vol.
5.30M
Volume
1.02K
52-wk high
$24.28
52-wk low
$2.46
EPS
-$0.95
Beta
0.68
Shares outstanding
349.76M
No. of employees
103
Open
$16.22
High
$16.27
Low
$15.16
Mkt. cap
5.52B
Avg. vol.
5.30M
Volume
1.02K
52-wk high
$24.28
52-wk low
$2.46
EPS
-$0.95
Beta
0.68
Shares outstanding
349.76M
No. of employees
103
News stories
From web sources and news partners
About Erasca Inc
CEO-
Employees103
Founded2018
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteerasca.com
Analyst ratings
Based on 4 analysts giving stock ratings to ERAS in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ERAS in the last 3 months.
Highest
Current $15.78
$33.00 (+109.13%)
Average
$26.00 (+64.77%)
Lowest
$20.00 (+26.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Hold
Maintained
$20.00
+26.7%
10/27/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$33.00
+109.1%
09/01/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$21.00
+33.1%
08/17/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$30.00
+90.1%
08/17/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$21.00
+33.1%
08/12/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$22.00
+39.4%
08/12/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$22.00
+39.4%
08/12/2026
Maury Raycroft
Jefferies
Buy
Reiterated
$24.00
+52.1%
07/14/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$26.00
+64.8%
05/12/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$24.00
+52.1%
04/28/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$20.00
+26.7%
03/06/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.15 / -$0.13
-15.23%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.47M
23.24M
27.26M
35.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.07M
9.36M
10.65M
11.72M
Operating expense
32.55M
32.60M
37.91M
47.62M
Total operating expenses
32.55M
32.60M
37.91M
47.62M
Operating income
-32.55M
-32.60M
-37.91M
-47.62M
Other non operating income
-37.00K
-54.00K
22.00K
-63.00K
EBT including unusual items
-30.61M
-29.09M
-183.44M
-44.08M
EBT excluding unusual items
-28.61M
-29.09M
-33.44M
-44.08M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-30.61M
-29.09M
-183.44M
-44.08M
Net profit margin
-
-
-
-
Earnings per share
-0.11
-0.10
-0.60
-0.14
Interest and investment income
3.97M
3.57M
4.45M
3.60M
Interest expense
-
-
-
-
Net interest expenses
3.97M
3.57M
4.45M
3.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.79M
-31.86M
-37.19M
-46.90M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps